NASDAQ : DCOY
Decoy Therapeutics Inc. — Key statistics
Healthcare · Biotechnology · United States
Last price 1.23 USD (Oct 29, 2026, 4:00 PM EDT) · Market cap 805.88K
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Key statistics
Valuation
| Measure | Value |
|---|
| Market Cap | 701,048 |
| Enterprise Value | -7.59M |
Dates
| Measure | Value |
|---|
| Earnings Date | Nov 16, 2026 |
| Ex-Dividend Date | n/a |
Shares
| Measure | Value |
|---|
| Current Share Class | 655,185 |
| Shares Outstanding | 655,185 |
| Shares Change (YoY) | +319.16% |
| Shares Change (QoQ) | n/a |
| Owned by Insiders (%) | 10.49% |
| Owned by Institutions (%) | 1.19% |
| Float | 586,437 |
Ratios
| Measure | Value |
|---|
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 3.08 |
| Forward PS | n/a |
| PB Ratio | 0.13 |
| P/TBV Ratio | 0.16 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Evratios
| Measure | Value |
|---|
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financialposition
| Measure | Value |
|---|
| Current Ratio | 1.83 |
| Quick Ratio | 1.77 |
| Debt / Equity | n/a |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financialefficiency
| Measure | Value |
|---|
| Return on Equity (ROE) | -827.77% |
| Return on Assets (ROA) | -73.35% |
| Return on Invested Capital (ROIC) | -218.37% |
| Return on Capital Employed (ROCE) | -141.15% |
| Weighted Average Cost of Capital (WACC) | 8.33% |
| Revenue Per Employee | $20,694 |
| Profits Per Employee | -$1.31M |
| Employee Count | 11 |
| Asset Turnover | 0.04 |
| Inventory Turnover | n/a |
Taxes
| Measure | Value |
|---|
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stockprice
| Measure | Value |
|---|
| Beta (5Y) | 0.74 |
| 52-Week Price Change | -97.68% |
| 50-Day Moving Average | 2.16 |
| 200-Day Moving Average | 5.51 |
| Relative Strength Index (RSI) | 34.11 |
| Average Volume (20 Days) | 74,982 |
Shortselling
| Measure | Value |
|---|
| Short Interest | 97,605 |
| Short Previous Month | 150,336 |
| Short % of Shares Out | 14.90% |
| Short % of Float | 16.64% |
| Short Ratio (days to cover) | 0.02 |
Incomestatement
| Measure | Value |
|---|
| Revenue | 227,629 |
| Gross Profit | -1.63M |
| Operating Income | -6.10M |
| Pretax Income | -14.45M |
| Net Income | -14.45M |
| EBITDA | -6.07M |
| EBIT | -6.10M |
| Loss Per Share | -$40.40 |
Balancesheet
| Measure | Value |
|---|
| Cash & Cash Equivalents | 8.29M |
| Total Debt | n/a |
| Net Cash | 8.29M |
| Net Cash Per Share | $12.65 |
| Equity (Book Value) | 4.32M |
| Book Value Per Share | 8.12 |
| Working Capital | 3.89M |
Cashflow
| Measure | Value |
|---|
| Operating Cash Flow | -8.32M |
| Capital Expenditures | -42,424 |
| Depreciation & Amortization | 24,495 |
| Net Borrowing | n/a |
| Free Cash Flow | -8.37M |
| FCF Per Share | -$12.77 |
Margins
| Measure | Value |
|---|
| Gross Margin | n/a |
| Operating Margin | -2,679.30% |
| Pretax Margin | -6,347.85% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends
| Measure | Value |
|---|
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -319.16% |
| Shareholder Yield | n/a |
| Earnings Yield | -3,775.35% |
| FCF Yield | -1,193.49% |
Analystforecasts
| Measure | Value |
|---|
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Stocksplits
| Measure | Value |
|---|
| Last Split Date | Mar 9, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:12 |
Scores
| Measure | Value |
|---|
| Altman Z-Score | -16.63 |
| Piotroski F-Score | 2 |
Fairvalue
| Measure | Value |
|---|
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |